Want to see APYX full AI Analyst Report?
Apyx Medical (APYX) AI Stock Analysis
Apyx Medical
(NASDAQ:APYX)
APYX scores low-to-mid primarily due to weak financial performance (ongoing losses, negative operating/free cash flow, and leverage risk). Technicals also weigh on the score with a clear downtrend despite oversold readings. These negatives are partially offset by a constructive earnings call featuring reaffirmed growth and margin guidance plus regulatory/product momentum, while valuation is difficult to support given negative earnings and no dividend.
Apyx Medical (APYX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $109.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 142.53K
- Price to Earnings (P/E)
- -12.6
- Beta (1Y)
- 1.77
- Revenue Growth
- 25.59%
- EPS Growth
- 55.35%
- Country
- US
- Employees
- 205
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Apyx Medical Business Overview & Revenue Model
Company Description
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics...
How the Company Makes Money
Apyx Medical primarily generates revenue by selling its energy-based capital equipment systems (notably the Renuvion platform) to healthcare providers and facilities, and by selling recurring-use products that are consumed during procedures. The reve...
Apyx Medical Earnings Call Summary
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reaffirmed full‑year 2026 guidance of total revenue of $59.0–$60.0 million (vs. $52.8M in 2025), with Surgical Aesthetics revenue of $54.0–$55.0 million (vs. ≈$45.3M) and OEM revenue of ≈$5.0 million (vs. ≈$7.5M), gross margins of 62–63%, and total operating expenses not to exceed $45.0 million; the outlook assumes AYON uptake (Power Lipo is embedded in the guidance), working‑capital management and strict cost controls, does not include potential tariff refunds, and management noted cash and cash equivalents of $27.6 million at June 30, 2026 with expected sufficient liquidity into 2028.
Apyx Medical Financial Statement Overview
Summary
Financials show stabilization but remain weak overall: revenue is modestly higher (+4.5% TTM) and losses have narrowed, yet profitability is still negative (TTM net margin ~-14.8%) and cash flow remains a major drag (negative operating cash flow and free cash flow in TTM). Leverage adds risk with a thin equity base relative to debt, limiting flexibility despite some improvement versus prior periods.
Income Statement
36NegativeBalance Sheet
42NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.41M | 52.84M | 48.10M | 52.35M | 44.51M | 48.52M |
| Gross Profit | 19.83M | 19.03M | 29.36M | 33.76M | 29.13M | 33.60M |
| EBITDA | -1.60M | -4.59M | -16.80M | -18.11M | -22.01M | -13.91M |
| Net Income | -8.63M | -11.21M | -23.46M | -18.71M | -23.18M | -15.17M |
Balance Sheet | ||||||
| Total Assets | 61.07M | 66.84M | 64.84M | 79.24M | 51.77M | 68.72M |
| Cash, Cash Equivalents and Short-Term Investments | 27.62M | 31.74M | 31.74M | 43.65M | 10.19M | 30.87M |
| Total Debt | 39.63M | 39.34M | 38.76M | 38.50M | 796.00K | 305.00K |
| Total Liabilities | 49.98M | 52.01M | 50.51M | 52.32M | 13.98M | 14.71M |
| Stockholders Equity | 10.66M | 14.54M | 14.21M | 26.70M | 37.58M | 53.70M |
Cash Flow | ||||||
| Free Cash Flow | -11.05M | -9.12M | -18.77M | -5.78M | -21.29M | -11.17M |
| Operating Cash Flow | -10.13M | -8.00M | -18.05M | -5.25M | -20.28M | -10.45M |
| Investing Cash Flow | -920.00K | -1.11M | -722.00K | 6.73M | -1.01M | -723.00K |
| Financing Cash Flow | 9.61M | 9.58M | 6.75M | 32.17M | 217.00K | 24.00K |
Apyx Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APYX, the sentiment is Neutral. The current price of 2.60 is above the 20-day moving average (MA) of 2.53, below the 50-day MA of 2.77, and below the 200-day MA of 3.60, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 49.16 is Neutral, neither overbought nor oversold. The STOCH value of 89.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APYX.
Apyx Medical Risk Analysis
Apyx Medical disclosed 28 risk factors in its most recent earnings report. Apyx Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksApyx Medical Peers Comparison
Overall Rating
ANIK61.9Neutral
RCEL54Neutral
XTNT45Neutral- APYX45Neutral
NSPR41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ANIK | 62Neutral | $280.37M | -77.74 | -2.70% | ― | -2.50% | 93.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| RCEL | 54Neutral | $484.01M | -10.79 | 231.87% | ― | 1.00% | 26.76% |
| XTNT | 45Neutral | $39.31M | -3.40 | -23.45% | ― | -14.27% | -132.84% |
| APYX | 45Neutral | $109.52M | -12.58 | -78.70% | ― | 25.59% | 55.35% |
| NSPR | 41Neutral | $20.92M | -0.91 | -79.21% | ― | 53.42% | 22.08% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| APYX | Apyx Medical | 2.60 | -0.60 | -18.75% | |
| ANIK | Anika Therapeutics, Inc. | 20.95 | 11.13 | 113.34% | |
| RCEL | Avita Medical Ltd | 15.65 | 11.87 | 314.02% | |
| NSPR | InspireMD Inc | 0.45 | -1.84 | -80.35% | |
| XTNT | Xtant Medical Holdings Inc | 0.28 | -0.53 | -65.47% |
Apyx Medical Corporate Events
Apyx Medical Highlights Renuvion Clinical Study Results
PositiveOn September 29, 2026, Apyx Medical announced results from a prospective clinical study published in Plastic and Reconstructive Surgery—Global Open, evaluating its Renuvion helium plasma radiofrequency technology on biological markers of skin q...
Apyx Medical Shareholders Back Board and Incentive Plan
PositiveOn August 6, 2026, Apyx Medical stockholders elected five directors to serve on the board until the 2027 annual meeting, reaffirming the company’s existing leadership structure. Shareholders also ratified RSM US LLP as the independent auditor f...
Apyx Medical Revamps Board Committees, Enhances Governance Oversight
PositiveOn July 24, 2026, Apyx Medical’s Board of Directors restructured the membership and leadership of its Audit, Governance and Nominating, Regulatory Compliance, and Compensation committees, appointing Lawrence J. Waldman, Minnie Baylor-Henry, and...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026